AB1012 management of breast cancer treatment induced bone loss- RE-audit
Abstract
Breast cancer treatment therapies (aromatase inhibitors (AI)) are associated with early menopause and adverse effect on bone density. Identifying high-risk patients and managing them appropriately will help reduce their fracture risk.We wanted to ascertain whether our management of breast cancer patients on aromatase inhibitors (AI) referred to osteoporosis clinic were as per guidelines. A consensus position statement from a UK expert group regarding breast cancer treatment induced bone loss, published with the support of the National Osteoporosis Society, the National Cancer Research Institute, Breast Cancer Study Group and the International Foundation.The guideline recommend lifestyle advice for low risk patients; calcium plus vitamin D supplementation and lifestyle advice for medium risk; bisphosphonate, calcium plus vitamin D supplementation and lifestyle advice for high risk.This is a re-audit cycle conducted for all patients referred to the osteoporosis clinic who were treated with aromatase inhibitors for breast cancer between 2016-2020. Patients were divided into two algorithms:Algorithm 1: women who had experienced premature menopause associated with ovarian suppression with or without AI.Algorithm 2: Postmenopausal women receiving treatment with an AI.T-scores were used to stratify patients in algorithm 1 into high risk (HR- T score -1).Algorithm 2 into high risk (HR-T score -1).Table 1.Showing the results of Audit 1 and Re-auditAudit 1Re-auditTotal…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.